Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 maintenance olaparib vs olaparib plus durvalumab in DDR-mutated unresectable or metastatic biliary tract cancer
KCT0006431Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, durvalumab in biliary cancer, gallbladder cancer, sponsored by AstraZeneca. Started Apr 2022; status: active, not recruiting.
02
Drugs
olaparibdurvalumab
03
Conditions
biliary cancergallbladder cancer
Beyond the preview
Go deeper on KCT0006431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006431.